跳转至内容
Merck
CN

Y0001238

(±)-磺吡酮

European Pharmacopoeia (EP) Reference Standard

别名:

1,2-二苯基-4-(苯亚砜基乙基)-3,5-吡咯烷二酮, 二苯基吡嗪酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C23H20N2O3S
CAS号:
分子量:
404.48
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24

等级

pharmaceutical primary standard

API类

sulfinpyrazone

制造商/商品名称

EDQM

应用

pharmaceutical (small molecule)

格式

neat

储存温度

2-8°C

SMILES字符串

O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4

InChI

1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

InChI key

MBGGBVCUIVRRBF-UHFFFAOYSA-N

基因信息

正在寻找类似产品? 访问 产品对比指南

一般描述

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.
For further information and support please go to the website of the issuing Pharmacopoeia.

应用

Sulfinpyrazone for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

包装

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

其他说明

Sales restrictions may apply.

象形图

Exclamation mark

警示用语:

Warning

危险声明

预防措施声明

危险分类

Acute Tox. 4 Oral

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


Choose from one of the most recent versions:

分析证书(COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact 客户支持

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Sulfinpyrazone: relationship between dose, kinetics, plasma concentrations and biological effects.
M R Buchanan
Thrombosis research. Supplement, 4, 89-92 (1983-01-01)
E H Margulies et al.
Drugs, 20(3), 179-197 (1980-09-01)
Sulfinpyrazone1 has long been recognised as a potent uricosuric agent, but has more recently been studied extensively as a platelet inhibitor and antithrombotic agent. It is active in man following oral administration and has been reported to be effective in
Uricosuric drugs, with special reference to probenecid and sulfinpyrazone.
A B Gutman
Advances in pharmacology, 4, 91-142 (1966-01-01)
Andrew C Kotze et al.
Antimicrobial agents and chemotherapy, 58(12), 7475-7483 (2014-10-08)
We used an enzyme induction approach to study the role of detoxification enzymes in the interaction of the anthelmintic compound naphthalophos with Haemonchus contortus larvae. Larvae were treated with the barbiturate phenobarbital, which is known to induce the activity of
Ashley M Laughney et al.
Science translational medicine, 6(261), 261ra152-261ra152 (2014-11-08)
Eribulin mesylate was developed as a potent microtubule-targeting cytotoxic agent to treat taxane-resistant cancers, but recent clinical trials have shown that it eventually fails in many patient subpopulations for unclear reasons. To investigate its resistance mechanisms, we developed a fluorescent

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门